apple
- 25 Mar 2004 20:47
hangon
- 03 Feb 2011 16:34
- 1375 of 1451
gibby - PYM is having its agm in London, soon. Will you attend? FWIW I suspect they want more money, hence attracting City types to the AGM (usually the arer in Godmanchester and only the Registrar travels there! HUh).
OXB- SP is taking a time to recover...any ideas? Volumes of Sell outweigh Buys (today 7:1)- ooer that's looking pretty poor.
tabasco - I'm guessing you are reasonably bullish, any comment on current sp? - and did OXB tell us about that Mfr option?
I just don't believe they need it - yet as a LT deal it makes sense, but I don't know what capacity this facility has* - or IF it needs more cash to get it on-line. Was it a good-deal I wonder?
The SP is telling otherwise...
PYM (ditto,) ==pair of smelly eggs - but which is rotten?
*but yr post 31Jan helps.
tabasco
- 05 Feb 2011 18:07
- 1376 of 1451
Hangonthis might help.
http://www.oxfordtimes.co.uk/business/8828490.BioMedica_buys_mothballed_plant/
With OXB eventually recruiting another 35-40 high-tech jobs for their manufacturing plantthey must be extremely confident covering that additional huge costor know more than they are saying? my guess is Sanofi-Aventis have made some guarantees?I believe SA have a trading update next week
This stock is definitely a puntbut I fancy the odds strongly at this 5-6p levelmight prove to be very tastywith a bit of luck?
hangon
- 07 Feb 2011 15:16
- 1377 of 1451
tabasco - thanks for the link, I wondered this wasn't the old [AIM-]Cobra-plant (now gone away)...got out of that stinker, but their plant is fairly modern I guess.
tabasco, - er, why sanofi? They departed PDQ a while ago and gave OXB 14m (was it?), which I assume has been spent wisely...already.
I'm wondering if OXB has sent a few profs down to Sandwich, where Phizer is shutting shop. Far too expensive to "take-over" but there are bound to be a few who would be prepared to move to Oxford.
That Phizer plant was responsible for Viagra, which is soon off-patent... but some similar research is needed for OXB as I am concerned this Cancer-Co is taking too long to turn any profit....we don't need ideals - - - - - we need "product-sales" and nothing so far.
This puts OXB in the same sad-basket as PYM...who have yet to sell one tin of weight-reduction.......Grr.
Toya
- 07 Feb 2011 20:44
- 1378 of 1451
Tabasco: thanks for that link to the Oxford Times.
I did hear good things about OXB and ASM while working in Oxford a couple of years back. And yes Cynic: I did used to trade both these but got out of them a long time ago. I'm not tempted to risk any more funds on small biotechs and agree with ptholden that they are very risky businesses. Some do pull through, of course, but there are better places to go fishing I reckon.
tabasco
- 09 Feb 2011 07:34
- 1379 of 1451
Cheers Toya
They are not wasting a lot of time here then?
Oxford Biomedica PLC
09 February 2011
OXFORD BIOMEDICA APPOINTS JAMES CHRISTIE AS NEW HEAD OF MANUFACTURING
with immediate effect.
tabasco
- 09 Feb 2011 15:24
- 1380 of 1451
Just wonder if OXB are being held down by mm's in order for people to close their shortssome large sells going through
CMC
UK AIM Share Bets AIM share bets that remain open will be closed out at the closing price on 11 February 2011
tabasco
- 11 Feb 2011 08:02
- 1381 of 1451
Taken from another thread
Shares Mag 10/2/11 info:-
Gene therapy specialist Oxford Biomedica (OXB)has the funds in place to progress its very promising development pipeline, which includes treatments for a range of diseases, most notably cancer,Parkinsons disease and opthalmological disorders. Positive newsflow over the next 12 months should take the shareprice higher.
Sentiment in the stock was hit byDecembers heavily discounted that saw the Oxford-based firm raise 18.4million net of expenses. It placed 279 mil-lion shares and carried out an open offer of a further 121 million shares at 5p each.
Yet investors can take confidence from that deal. It was not only supported by existing institutional investors but by a number of heavy-hitting money managers who joined the share register for the first time.Gartmore (GRT)now owns 2.2% of the issued capital, Artemis 1.6% and Majedie Asset Management 1.5% respectively.
The money raised added to a year-end cash balance of 12million. It will be put to very good use and should enable the company to meet three key strategic objectives.
First, 8.2 million has been put aside to initiate a Phase II trial for Prosavin, Oxford Biomedicas key drug for a one-shot treatment for Parkinsons. Positive news (22Dec) on low-dose trials on humans found average motor function improvement of 26% with no serious adverse events. Higher, optimum dosage Phase I/II trials on humans started in January, with data available by mid-2011.Positive results should enable Oxford Biomedica to then seek a partner to share in the 50 million costs of stage II trials,planned for the second half of 2012. Chief executive John Dawson explains: We will need to do deals with Prosavin and in order to do them most effectively for shareholders we needed a strong balance sheet. Now we can proceed from a position of strength and structure any deal to share the costs of the trials so as to retain a territory, thereby obtaining a greater share of downstream returns. With any such deal will come upfront revenues and the prospect of future milestone payments and royalties that should be significantly earnings enhancing in the medium term.House broker Singer has calculated Prosavin could reach market by 2017 with the potential to generate sales of 628 million within five years of launch, and there-fore annual income to Oxford Biomedica of 113 million.
Second, the 52.5 million cap is establishing proprietary manufacturing facili-ties following the purchase (31 Jan) of a specialist site at a cost of 1.9 million. This should come onstream by mid-2012 after 2 million in additional investment. This will then provide sufficient capacity for the company to produce clinical products using its proprietary LentiVector gene delivery technology.
Finally, Oxford Biomedicas ocular pro-gramme is also progressing well. In December a US Phase I/II trial of RetinoStat for age-related macular degen-eration began. Results are expected by the first half of 2012 and if successful would see Sanofi-Aventis (SAN:PA)exercise its commercialisation option and trigger an estimated $20 million milestone. This could be a blockbuster and Singer estimates could generate royalty and annual manufacturing income to Oxford Biomedica worth 428 million by 2023.
Singers analyst Shawn Manning estimates the investment required to bring these plans to fruition will take group pre-tax losses up to 8.8 million in 2010 and7.8 million in 2011, as against the 5.1million deficit recorded in 2009. Yet he believes these losses will reduce significantly to just 700,000 loss in 2012.Providing suitable product partners are found Manning believes Oxford Biomedica could be profitable as soon as 2014. His 13p price target implies potential upside of 136%.Gene therapy company has funds in place to support product development.
Toya
- 11 Feb 2011 09:24
- 1382 of 1451
Hmm, odd that they seem to be waking up again... Maybe it'll be another blinking Blinkx? I can't believe I'm thinking of being tempted back in here!
tabasco
- 11 Feb 2011 10:38
- 1383 of 1451
A very bullish reportThe figures are telephone numbers..and I am not deterred by the time scalesthe higher optimum dosage Phase I/II Prosavin trials on humans started in January data available June/Julyif there is a sniff of success we will have many partnership offers to consider imobetter still with a manufacturing plant in placethe ocular programme and TroVax cancer vaccine we could get taken out pretty quick.I think there is very little risk at these levelsand I dont think you will have to wait that long for a nice paydayjust a view from a lucky thicko?
tabasco
- 11 Feb 2011 10:48
- 1384 of 1451
I dont think 6p will be available much longer?
tabasco
- 15 Feb 2011 10:18
- 1385 of 1451
Make that 7p.the recent buying suggests good news on the way?
tabasco
- 15 Feb 2011 10:56
- 1386 of 1451
Does someone know the patient reaction to first 5x dosing....or is the reported Sanofi-Aventis $1.35 Billion set aside for Eye-Care Acquisitions...ringing bells?
tabasco
- 15 Feb 2011 13:23
- 1387 of 1451
Anyone keeping an eye on this constant buying?.. Expect news.this is not the OXB that I know7p gone...
tabasco
- 02 Mar 2011 07:06
- 1388 of 1451
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2010
Share this article
TIDMOXB
RNS Number : 1393C
Oxford Biomedica PLC
02 March 2011
2011/OB/04
EMBARGOED UNTIL 7.00AM 2 MARCH 2011 2 MARCH 2011
OXFORD BIOMEDICA PLC
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2010
Oxford, UK - 2 March 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces its preliminary results for the year ended 31 December 2010.
Operational highlights:
ProSavin(R) : Parkinson's disease
-- Safety and tolerability endpoints sustained for >2 years, now extended to nine patients
-- Two-year Phase I/II data indicate long-term efficacy at lowest (1x) dose level
-- Improvements in "ON" time and quality of life, with stable or reduced L-DOPA, in all cohorts to date
-- Enhanced administration procedure is safe and reduced surgery delivery time at the 2x dose
-- Data Monitoring Committee supports progression to higher (5x) dose level cohort with initial data expected mid-2011
Ocular gene therapies: partnered with sanofi-aventis
-- RetinoStat(R) IND approval received from the FDA
-- StarGen(TM) CTA and IND dossiers submitted to AFSSAPS and FDA
-- First data from RetinoStat(R) Phase I study expected H1 2012
TroVax(R) : cancer
-- Phase II study in hormone refractory prostate cancer initiated with initial data expected from mid-2012
-- Positive TRIST analyses published in Clinical Cancer Research
-- Multiple collaborative studies expected to start in 2011
Financial highlights(1) :
-- Revenue of GBP11.2 million (2009: GBP19.1 million including exceptional revenue GBP10.1 million)
-- Research & development costs incl. exceptional items of GBP19.9 million (2009: GBP18.3 million)
-- Exceptional loss (impairment) of GBP3.9 million (2009: exceptional profit of GBP6.0 million)
-- Net loss before exceptional items of GBP6.3 million (2009: GBP9.5 million)
-- Net loss after exceptional items of GBP10.3 million (2009: GBP3.5 million)
-- Net cash burn(2) of GBP13.0 million (2009: net cash generated(2) GBP3.0 million)
-- Net cash(3) of GBP12.3 million (2009: GBP25.3 million)
1. Audited financial results
2. Net cash used in /generated from operating activities plus sales and purchases of non-current assets and interest received
3. Cash, cash equivalents and available for sale investments
Post-period end highlights:
-- Fundraising of GBP20 million before expenses, completed on 10 January 2011
-- Acquisition of manufacturing facility for GBP1.9 million, completed in February 2011
John Dawson, Chief Executive Officer at Oxford BioMedica, said: "2010 has been a successful year for Oxford BioMedica and our progress to date underlines the Company's strong fundamentals. We continue to build the value of our lead programmes and expect key data and milestones over the next 12-18 months for ProSavin(R) , TroVax(R) and the ocular products partnered with sanofi-aventis. Thanks to existing and new shareholders we were also able to secure GBP20 million of funding which will enable us to maximise the opportunities ahead, including the enhancement of our specialist manufacturing processes. With exciting future prospects, we remain committed to driving momentum and delivering value for shareholders."
-Ends
hangon
- 14 Mar 2011 13:36
- 1389 of 1451
All looks very good, except they haven't got a regular product to sell, so all of the above is window-dressing before the shop opens, (as it were). I hold this and recent placing, but the sp is refusing to leap into double figures despite what looks like a "good deal" =looking to the future, with that manufacturing plant.
Having their stuff made in-house should provide them with a strong hand in negotiations.....initially they can sell direct can't they?
But still the sp is not really responding well. Maybe a case of soon taking some nasty medicine - Oh No!
EDIT(5May2011)-AGM today and SP is barely 5p despite all that Cash and Potential. Recent ann. Director Options look like they've caught the same bug affecting most of the AIM market Co's. - that of fine words and no Deeds. We need a return to shareholder power - by which I mean those that pay their own money for shares....which is Thee and Me...not Institutions or Freebe handouts.
EDIT(19Jy2011)- 6.6p Yikes! up 10% on Buy, but probably not after Dealer charges, etc... However, general markets are jumpy, yet again.
EDIT (18Nov2011):- Oh deary, 5p for quite some while - no news, little excitement.
tabasco
- 04 Jul 2011 08:57
- 1390 of 1451
With 60mil shares traded over the last five days inclusive of today there is news on the waythat is a done deal!OXB have always had news leaks and this appears to be something substantial
Slight SP movement but hunch says a big day round the cornerrememberI will never use all my luck up!! Dyor.
Dil
- 04 Jul 2011 23:08
- 1391 of 1451
Oh ffs tabby another wing and a prayer job you got in at a much higher price.
Stick to mks.
tabasco
- 05 Jul 2011 06:23
- 1392 of 1451
Dil what are you like on logarithms or compound multiplication?not too good I would presumemy combined accounts are showing a double digit profit at this moment in time on OXBare you forgetting I am invincible!with you posting on the MDX thread along with the nobssuggest you are trying to provoke a situation
Im too happy mate!!! Family retired on BLNX alonethen SER came along.whoooooooshplus another on the wayIll tell you about it later. But I am still capable of telling a few to fcuk off!! So dont get cheeky..
tabasco
- 07 Jul 2011 18:15
- 1393 of 1451
Dilwhat are you one day on three months off?listenafter speaking with my usual crew I have a hunch that there is significant interest in this stock No ramp intended
Keep an eye on the trading patternsOXB are not very good at keeping secretsdont say I havent pointed you in the right directionJKDI am also telling you now OK?no silly post after the event please
Watch this space
tabasco
- 08 Jul 2011 11:03
- 1394 of 1451
Continued one-sided trading.what gives?